The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
Researchers catalogued 1,067 small proteins missing from a reviewed reference database and linked one to mitochondrial function in laboratory microglia. The findings expand Alzheimer’s research tools, while leaving treatment and prevention benefits untested.
Australian regulators reported finding undeclared semaglutide and no retatrutide in a product investigated after a hospitalization. The case highlights an ingredient-identity risk while leaving the frequency of such substitutions unknown.
A South African surveillance study connects fine-particle pollution with invasive pneumococcal infections, with the highest pollution-associated risk among older adults. The observational findings suggest bacterial diversity matters when assessing environmental health risks.
A human study connects less coordinated brain waves during sleep with frontal tau accumulation and weaker overnight memory retention. The findings identify a possible mechanism in cognitive aging, without establishing a preventive treatment.
A small first-in-human study supports further testing of ACCG-2671, a non-peptide drug targeting amylin and calcitonin receptors. Exploratory weight changes came alongside frequent nausea and vomiting in the highest-dose group.
Researchers found that protein patterns associated with metabolic risk in children also tracked disease outcomes in adult cohorts. The findings support further prevention research but do not establish a screening test or treatment strategy for children.
A study of 18,734 responders connects residential environmental conditions with physical and mental-health measures. The observational findings identify prevention questions without establishing that neighborhood changes would improve healthspan.
A July study found that acute cariprazine treatment improved two memory tests and synaptic plasticity in two mouse models. The result is preliminary, and the antipsychotic is neither approved nor established as an Alzheimer’s treatment.
The small, sponsor-reported study supports further investigation. Whether the peptide slows Parkinson’s disease remains unanswered.
Researchers found associations between an imaging-derived age estimate, cognitive performance and gut biological signatures. The cross-sectional findings support further research but do not establish a test that predicts future dementia.
New mechanistic research strengthens the case for investigating the brain’s vascular barrier as an Alzheimer’s target. Clinical benefit remains untested.
The planned 86-participant study will assess safety and how the investigational peptide behaves in people. Animal findings reported by the developer do not establish human weight-loss benefits.